PersonaCRC turns metastatic uncertainty into treatment clarity.

PersonaCRC assesses the risk of spread, recurrence, and overall survival, to help clinicians identify the most effective treatment strategies and improve patient outcomes.

Metastasis accounts for the majority of cancer-related deaths, and treatment decisions are often made without clear prognostic tools. PersonaCRC provides evidence-based stratification to support more precise decision-making. By integrating RNA sequencing data with clinical insights, our platform stratifies metastatic colorectal cancer into low, intermediate, and high-risk groups with over 90% accuracy.

This clarity empowers clinicians to:

• Identify which patients are most likely to benefit from curative local therapy versus those who require systemic treatment.

• Avoid unnecessary or ineffective systemic treatments

• Provide patients with evidence-based guidance at a critical decision point

PersonaCRC Key Outcomes:

PersonaCRC is supported by decades of research and independently validated with Phase 3 New EOPC trial data.

• >90% accuracy in classifying colorectal liver metastases

• 50% difference in 5-year survival between low- and high-risk groups

• Identification of a low-risk subgroup with markedly improved survival and potential for cure

Actionable Reporting

Clear risk tiers and therapy guidance, with results delivered within 48 hours of sequencing data.

Validated Biomarker Technology

Validated performance: Independent validation with Phase 3 trail data, peer-reviewed, with over 90% accuracy.

Impactful Patient Outcomes

Avoids unnecessary treatments, and reduces costs.

PersonaCRC provides integrated prognostic risk classification to personalize treatment decisions— helping clinicians precisely define disease biology, manage patients with confidence, and identify those with potential for cure.

Ordering Process:

1. Physician Orders Test

   The treating physician orders the PersonaCRC test for their patient with the test request form (TRF)

2. Tissue Sample Sent

   The liver metastasis tissue is sent to Caris Life Sciences for RNA sequencing. Sequencing data are then securely transferred via AWS to Protean BioDiagnostics. No additional procedures are required from the patient.

3. AI Analysis

   PersonaDx applies its proprietary AI model to generate a molecular subtype and integrated risk group.

4. Results & Treatment Plan

   A Protean BioDiagnostics board-certified pathologist reviews the analysis and delivers the final clinician-ready report to guide treatment planning.